Search results for Moderna
AI & Enterprise
AI fear-battered stocks revive in August U.S. market rebound lineup
In August, U.S. stocks that had been weighed down by Wall Street’s bearish narratives rebounded sharply, CNBC reported. Jim Cramer said worries over AI threats, slower growth and worsening conditions were overturned by earnings and shifts in positioning. Moderna surged after reporting promising results for an experimental melanoma vaccine with Merck. Enterprise software names rebounded as a high-leverage hedge fund unwound bets. Other gainers included Gartner, Newmont, Paramount Skydance, Super Micro Computer, Sandisk and Coinbase.
Industry
Moderna shares surge 177 percent after success in phase 3 trial for mRNA cancer vaccine
Moderna shares jumped about 177 percent in a single day after the company reported positive results from the first phase 3 clinical trial of a personalised mRNA-based cancer treatment. Moderna said its intismeran autogene, used with Merck\'s Keytruda, met the main endpoints in the INTerpath-001 trial in patients with stage 2B to 4 melanoma after tumour removal surgery. Merck shares also rose. Short sellers\' losses widened to about $4.8 billion.
Industry
Hantavirus fears revive COVID-19 beneficiary stocks; Moderna and BioNTech in focus
Rising concerns about a possible spread of hantavirus are pushing medical and vaccine-related stocks back into focus after gaining attention during the COVID-19 pandemic. BeInCrypto reported that Moderna, Emergent BioSolutions and BioNTech entered reassessment phases in May. Moderna shares rose on stronger first-quarter sales, vaccine cooperation news and flu vaccine trial data publication. Emergent is focused on confirming a bottom amid weaker guidance. BioNTech faces a bearish technical pattern despite maintained revenue guidance.